Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Surface Pharmaceuticals logo — Enhancing ocular health with advanced topical solutions for...

Surface Pharmaceuticals

Enhancing ocular health with advanced topical solutions for timely and effective dry eye disease recovery.

Founded 2017 Venture round Total: $46.76M Biopharma, Health Care +1

General Information

Company Name Surface Pharmaceuticals
Founded Year 2017
Founders / Decision Makers
Team member
Industries Biopharma, Health Care, Pharmaceutical
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with Surface Pharmaceuticals. To contact Surface Pharmaceuticals, visit surfacepharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Surface Pharmaceuticals compare?

A PDF of Surface Pharmaceuticals and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Surface Pharmaceuticals soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Surface Pharmaceuticals

Surface Pharmaceuticals is a biopharmaceutical startup founded in 2017 that is dedicated to enhancing ocular health through advanced topical solutions for timely and effective dry eye disease recovery. The company's slogan encapsulates its mission to provide innovative ophthalmology solutions through the utilization of the propriety Klarity delivery system. This unique approach aims to safeguard and restore the ocular surface, catering to the needs of patients suffering from dry eye disease. Having recently secured a significant $5.76M Venture Round investment on 10 June 2021, Surface Pharmaceuticals demonstrates promising potential within the biopharma, health care, and pharmaceutical industries. Despite the lack of specific headquarters information, the startup's focus on leveraging advanced topical formulations signifies a commitment to driving advancements in ocular health. The recent investment signifies confidence from investors in the company's innovative approach to addressing dry eye disease. This funding injection is expected to further propel Surface Pharmaceuticals' efforts in developing effective and timely recovery solutions for patients. As the company continues to pioneer advancements in ocular health, its recent investment underscores the potential for growth and impact within the pharmaceutical and biopharmaceutical sectors.

Business keywords: Ocular health, Topical solutions, Dry eye disease, Pharmaceuticals, Ophthalmology solutions, Topical formulations, Medications, Klarity delivery system, Recovery, Ocular surface, Proprietary technology, Eye care, Medical technology, Innovation

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $5.76M -
10 Jun 2021
Series A $21.00M 1
Visionary Ventures
Visionary Ventures
11 Jul 2018
Series A $20.00M 1
Flying L Partners
Flying L Partners
15 May 2018

Surface Pharmaceuticals Alternatives & Competitors

View All Alternatives
Surface Pharmaceuticals vs
Tsubota Laboratory, Inc.
Tsubota Laboratory, Inc. Japan

Through innovation in health and medical fields, we will make the world happier and healthier

Venture round
11 employees
Health Care, Medical Devices
Surface Pharmaceuticals vs
Novaliq GmbH
Novaliq GmbH Germany

Transforming Ocular Therapeutics

Series F+
23 employees
Biotechnology, Health Care
Surface Pharmaceuticals vs
EternaTear
EternaTear United States

Next Generation Artificial Tear for Dry Eye

Series A
2 employees
Health Care, Health and Wellness
View all alternatives

FAQ About Surface Pharmaceuticals

Enhancing ocular health with advanced topical solutions for timely and effective dry eye disease recovery.
Surface Pharmaceuticals was founded in 2017.
Surface Pharmaceuticals operates in Biopharma, Health Care and Pharmaceutical. Its work centres on Ocular health, Topical solutions, Dry eye disease and Pharmaceuticals.
Surface Pharmaceuticals has completed 3 funding rounds, raising a total of $46.76M. The latest funding stage is Venture round.
Top alternatives and competitors to Surface Pharmaceuticals include Tsubota Laboratory, Inc., Novaliq GmbH, EternaTear, EyeD Pharma, Orasis Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Surface Pharmaceuticals and Tsubota Laboratory, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Surface Pharmaceuticals, https://bouncewatch.com/company/surface-pharmaceuticals, updated 26 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes